Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Assets Average (2016 - 2025)

Historic Assets Average for Karyopharm Therapeutics (KPTI) over the last 13 years, with Q4 2025 value amounting to $102.3 million.

  • Karyopharm Therapeutics' Assets Average fell 4217.25% to $102.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $102.3 million, marking a year-over-year decrease of 4217.25%. This contributed to the annual value of $136.4 million for FY2025, which is 3260.96% down from last year.
  • Karyopharm Therapeutics' Assets Average amounted to $102.3 million in Q4 2025, which was down 4217.25% from $100.6 million recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Assets Average registered a high of $342.0 million during Q1 2023, and its lowest value of $100.6 million during Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' median Assets Average value was $262.8 million (recorded in 2021), while the average stood at $235.3 million.
  • Its Assets Average has fluctuated over the past 5 years, first skyrocketed by 1641.86% in 2023, then plummeted by 5015.26% in 2025.
  • Karyopharm Therapeutics' Assets Average (Quarter) stood at $279.7 million in 2021, then grew by 5.36% to $294.7 million in 2022, then dropped by 13.4% to $255.2 million in 2023, then plummeted by 30.66% to $176.9 million in 2024, then plummeted by 42.17% to $102.3 million in 2025.
  • Its Assets Average was $102.3 million in Q4 2025, compared to $100.6 million in Q3 2025 and $116.3 million in Q2 2025.